301 †FC, fecal calprotectin; BMI, body mass index; HBI, Harvey Bradshaw Index; TNF, tumor necrosis factor; CRP, C-reactive protein; ESR, erythrocyte sedimentation rate; WBC, white blood cell count. Differences between groups were tested using the independent sample t-test or Mann-Whitney U-test for continuous variables and the Fisher’s exact test for discontinuous variables, as appropriate. Two-sided P-values < 0.05 were considered as statistically significant. *P < 0.05; **P < 0.01; ***P < 0.001. Urinary 52Cr-EDTA/creatinine excretion proportionally increases with fecal calprotectin levels Distributions of the 24-h urinary 52Cr-EDTA/creatinine ratio among both groups are shown in Figure 1A. CD patients with increased fecal calprotectin levels showed a trend of elevated urineexcreted 52Cr-EDTA/creatinine (771.8 μmol/mol (IQR: 472.4-1005.9) vs. 636.4 μmol/mol (IQR: 365.0843.4), P = 0.132). Importantly, we observed a significant correlation between urinary 52Cr-EDTA/ creatinine excretion and fecal calprotectin levels (ρ = 0.325, P < 0.05, Figure 1B), while controlling for gender, disease localization, ileocecal resection status and alcohol consumption. Figure 1 | The relationship between levels of urinary 24-h 52Cr-EDTA/creatinine excretion and fecal calprotectin. (A) Distribution of urinary 52Cr-EDTA/creatinine excretion in patients with low (blue, < 100 μg/g) and increased (red, > 100 μg/g) fecal calprotectin levels, shown in boxplots. (B) Urinary 52Cr-EDTA/ creatinine excretion significantly correlates with fecal calprotectin levels (ρ = 0.325, P < 0.05), as represented by the red smoothed curve. 52Cr-EDTA intestinal permeability in Crohn’s disease Montreal, Localization 0.476 L1 (ileal) 12 (48.0) 12 (34.3) L2 (colonic) 4 (16.0) 5 (14.3) L3 (ileocolonic) 9 (36.0) 18 (51.4) Montreal, Behavior 0.642 B1 (non-stricturing, nonpenetrating) 11 (44.0) 18 (51.4) B2 (stricturing) 9 (36.0) 13 (37.1) B3 (penetrating) 5 (20.0) 4 (11.4) Laboratory values CRP (mg/L) 0.9 [0.5;3.3] 2.6 [0.9;5.0] 0.052 ESR (mm/h) 8.0 [3.0;18.0] 13.0 [9.0;27.0] 0.028* WBC (x109/l) 6.4 ± 1.6 7.8 ± 2.2 0.013* FC (µg/g) 45 [40;67] 360 [175;760] <0.001*** Thrombocytes (x109/l) 288 ± 82 287 ± 67 0.776 Creatinine (μmol/l) 75 ± 15 71 ± 11 0.245 †FC, fecal calprotectin; BMI, body mass index; HBI, Harvey Bradshaw Index; TNF, tumor necrosis factor; CRP, Creactive protein; ESR, erythrocyte sedimentation rate; WBC, white blood cell count. Differences between groups were test d using the independent ample t-test or Mann-Whitney U-test for co tinuous variables and th Fisher’s exact test for discontinuous variables, as appropriate. Two-sided P-values < 0.05 were considered as statistically significant. *P < 0.05; **P < 0.01; ***P < 0.001.
RkJQdWJsaXNoZXIy MjY0ODMw